home / stock / fstx / fstx quote
Last: | $7.12 |
---|---|
Change Percent: | 0.14% |
Open: | $7.11 |
Close: | $7.12 |
High: | $7.12 |
Low: | $7.11 |
Volume: | 987,072 |
Last Trade Date Time: | 03/08/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$7.12 | $7.11 | $7.12 | $7.12 | $7.11 | 987,072 | 03-08-2023 |
$7.12 | $7.1 | $7.12 | $7.12 | $7.09 | 9,674,943 | 03-07-2023 |
$6.1 | $5.75 | $6.1 | $6.12 | $5.72 | 409,836 | 03-06-2023 |
$5.5 | $5.64 | $5.5 | $5.8 | $5.4 | 331,662 | 03-03-2023 |
$5.69 | $5.56 | $5.69 | $5.75 | $5.51 | 99,738 | 03-02-2023 |
$5.6 | $5.33 | $5.6 | $5.7 | $5.33 | 114,344 | 03-01-2023 |
$5.35 | $5.6 | $5.35 | $5.72 | $5.33 | 154,314 | 02-28-2023 |
$5.6 | $5.9 | $5.6 | $5.9 | $5.28 | 351,855 | 02-27-2023 |
$5.89 | $5.68 | $5.89 | $5.89 | $5.6155 | 291,731 | 02-24-2023 |
$5.71 | $4.99 | $5.71 | $5.74 | $4.84 | 1,119,330 | 02-23-2023 |
$4.7 | $4.68 | $4.7 | $4.85 | $4.66 | 108,672 | 02-22-2023 |
$4.76 | $4.91 | $4.76 | $4.91 | $4.59 | 184,133 | 02-21-2023 |
$4.98 | $5.01 | $4.98 | $5.06 | $4.7635 | 450,792 | 02-20-2023 |
$4.98 | $5.01 | $4.98 | $5.06 | $4.7635 | 450,792 | 02-17-2023 |
$4.92 | $4.8 | $4.92 | $5.0848 | $4.79 | 179,794 | 02-16-2023 |
$4.8 | $4.78 | $4.8 | $4.87 | $4.76 | 95,787 | 02-15-2023 |
$4.78 | $4.82 | $4.78 | $4.84 | $4.7 | 93,177 | 02-14-2023 |
$4.84 | $4.78 | $4.84 | $4.91 | $4.62 | 254,020 | 02-13-2023 |
$4.82 | $4.72 | $4.82 | $4.86 | $4.5822 | 177,294 | 02-10-2023 |
$4.72 | $4.63 | $4.72 | $4.9 | $4.5 | 520,428 | 02-09-2023 |
News, Short Squeeze, Breakout and More Instantly...
F-star Therapeutics Inc Com Company Name:
FSTX Stock Symbol:
NASDAQ Market:
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWI...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”) , a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to t...
LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statemen...